|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:SLC19A1-ZADH2 (FusionGDB2 ID:81796) |
Fusion Gene Summary for SLC19A1-ZADH2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: SLC19A1-ZADH2 | Fusion gene ID: 81796 | Hgene | Tgene | Gene symbol | SLC19A1 | ZADH2 | Gene ID | 6573 | 284273 |
| Gene name | solute carrier family 19 member 1 | zinc binding alcohol dehydrogenase domain containing 2 | |
| Synonyms | CHMD|FOLT|IFC-1|IFC1|REFC|RFC|RFC1|RFT-1|hRFC|hSLC19A1 | PRG-3 | |
| Cytomap | 21q22.3 | 18q22.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | reduced folate transporterfolate transporter 1intestinal folate carrier 1placental folate transporterreduced folate carrier 1reduced folate carrier proteinreduced folate transporter 1solute carrier family 19 (folate transporter), member 1 | prostaglandin reductase 3zinc-binding alcohol dehydrogenase domain-containing protein 2 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | P41440 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000567670, ENST00000468508, ENST00000311124, ENST00000380010, ENST00000485649, | ENST00000322342, ENST00000537114, | |
| Fusion gene scores | * DoF score | 8 X 7 X 5=280 | 14 X 4 X 5=280 |
| # samples | 8 | 14 | |
| ** MAII score | log2(8/280*10)=-1.8073549220576 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(14/280*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: SLC19A1 [Title/Abstract] AND ZADH2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | SLC19A1(46945731)-ZADH2(72914295), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | SLC19A1-ZADH2 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. SLC19A1-ZADH2 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. SLC19A1-ZADH2 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | SLC19A1 | GO:0051958 | methotrexate transport | 22554803 |
| Hgene | SLC19A1 | GO:0098838 | folate transmembrane transport | 22554803 |
| Hgene | SLC19A1 | GO:1904447 | folate import across plasma membrane | 14609557|22554803 |
| Fusion gene breakpoints across SLC19A1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ZADH2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | ERR315486 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
Top |
Fusion Gene ORF analysis for SLC19A1-ZADH2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000567670 | ENST00000322342 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| 5CDS-5UTR | ENST00000567670 | ENST00000537114 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| intron-3CDS | ENST00000468508 | ENST00000322342 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| intron-5UTR | ENST00000468508 | ENST00000537114 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| Frame-shift | ENST00000311124 | ENST00000322342 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| 5CDS-5UTR | ENST00000311124 | ENST00000537114 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| Frame-shift | ENST00000380010 | ENST00000322342 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| 5CDS-5UTR | ENST00000380010 | ENST00000537114 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| Frame-shift | ENST00000485649 | ENST00000322342 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| 5CDS-5UTR | ENST00000485649 | ENST00000537114 | SLC19A1 | chr21 | 46945731 | - | ZADH2 | chr18 | 72914295 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for SLC19A1-ZADH2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for SLC19A1-ZADH2 |
| Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| SLC19A1 | . |
| FUNCTION: Transporter that mediates the import of reduced folates and a subset of cyclic dinucleotides (PubMed:7826387, PubMed:9041240, PubMed:10787414, PubMed:15337749, PubMed:16115875, PubMed:31126740, PubMed:31511694). Has high affinity for N5-methyltetrahydrofolate, the predominant circulating form of folate (PubMed:10787414, PubMed:14609557, PubMed:22554803). Also able to mediate the import of antifolate drug methotrexate (PubMed:7615551, PubMed:7641195, PubMed:9767079, PubMed:22554803). Acts as an importer of immunoreactive cyclic dinucleotides, such as cyclic GMP-AMP (2'-3'-cGAMP), an immune messenger produced in response to DNA virus in the cytosol, and its linkage isomer 3'-3'-cGAMP (PubMed:31126740, PubMed:31511694). Mechanistically, acts as an antiporter, which export of intracellular organic anions to facilitate uptake of its substrates (PubMed:22554803, PubMed:31126740, PubMed:31511694). 5-amino-4-imidazolecarboxamide riboside (AICAR), when phosphorylated to AICAR monophosphate, can serve as an organic anion for antiporter activity (PubMed:22554803). {ECO:0000269|PubMed:10787414, ECO:0000269|PubMed:14609557, ECO:0000269|PubMed:15337749, ECO:0000269|PubMed:16115875, ECO:0000269|PubMed:22554803, ECO:0000269|PubMed:31126740, ECO:0000269|PubMed:31511694, ECO:0000269|PubMed:7615551, ECO:0000269|PubMed:7641195, ECO:0000269|PubMed:7826387, ECO:0000269|PubMed:9041240, ECO:0000269|PubMed:9767079}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for SLC19A1-ZADH2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for SLC19A1-ZADH2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for SLC19A1-ZADH2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for SLC19A1-ZADH2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | SLC19A1 | C0004352 | Autistic Disorder | 2 | CTD_human |
| Hgene | SLC19A1 | C0013080 | Down Syndrome | 2 | CTD_human |
| Hgene | SLC19A1 | C0432416 | Down Syndrome, Partial Trisomy 21 | 2 | CTD_human |
| Hgene | SLC19A1 | C0432417 | Trisomy 21, Meiotic Nondisjunction | 2 | CTD_human |
| Hgene | SLC19A1 | C0751081 | Trisomy 21, Mitotic Nondisjunction | 2 | CTD_human |
| Hgene | SLC19A1 | C0001430 | Adenoma | 1 | CTD_human |
| Hgene | SLC19A1 | C0005684 | Malignant neoplasm of urinary bladder | 1 | CTD_human |
| Hgene | SLC19A1 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
| Hgene | SLC19A1 | C0007102 | Malignant tumor of colon | 1 | CTD_human |
| Hgene | SLC19A1 | C0008924 | Cleft upper lip | 1 | CTD_human |
| Hgene | SLC19A1 | C0008925 | Cleft Palate | 1 | CTD_human |
| Hgene | SLC19A1 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
| Hgene | SLC19A1 | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
| Hgene | SLC19A1 | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| Hgene | SLC19A1 | C0013221 | Drug toxicity | 1 | CTD_human |
| Hgene | SLC19A1 | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Hgene | SLC19A1 | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Hgene | SLC19A1 | C0027765 | nervous system disorder | 1 | CTD_human |
| Hgene | SLC19A1 | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| Hgene | SLC19A1 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Hgene | SLC19A1 | C0205646 | Adenoma, Basal Cell | 1 | CTD_human |
| Hgene | SLC19A1 | C0205647 | Follicular adenoma | 1 | CTD_human |
| Hgene | SLC19A1 | C0205648 | Adenoma, Microcystic | 1 | CTD_human |
| Hgene | SLC19A1 | C0205649 | Adenoma, Monomorphic | 1 | CTD_human |
| Hgene | SLC19A1 | C0205650 | Papillary adenoma | 1 | CTD_human |
| Hgene | SLC19A1 | C0205651 | Adenoma, Trabecular | 1 | CTD_human |
| Hgene | SLC19A1 | C1837218 | Cleft palate, isolated | 1 | CTD_human |
| Hgene | SLC19A1 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies